American Clinical Research Services (“ACRS”) has announced the acquisition of Clinical Site Services (“CSSi”) and Patient Advertising Guru (“PAG”). The acquisition of the two previously merged companies demonstrates ACRS’s focus on inclusive patient centric solutions for clinical development. Both Chris Trizna (CSSi) and Evan Brett (PAG) remain as co-Presidents, joining the ACRS leadership team.
Clinical Site Services is a provider of customized, full-service site centric patient recruitment solutions. CSSi’s Local Enrollment Specialists are former study coordinators, located across the globe, that support sites to generate referrals from within the site, their community, advocacy groups, and local medical practitioners.
Patient Advertising Guru is a niche provider of advertising, providing creative development, media buying, and referral tracking services. PAG is also the creator of Research Study Rockstar, a social media resource for patient recruitment.
Both CCSi and PAG have experience servicing a range of therapeutic areas, including oncology, CNS, metabolic, and women’s health, across 50+ countries.
Latticework Capital Management’s American Clinical Research Services Acquires Clinical Site Services and Patient Advertising Guru. (2023, May 9). Business Wire.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
First Patient Dosed in Phase III Trial of Enhertu as First-Line Treatment for Endometrial Cancer
June 10th 2025In combination with rilvegostomig or Keytruda, Enhertu will be evaluated versus chemotherapy in the DESTINY-Endometrial01 study for the treatment of patients with HER2-expressing, mismatch repair proficient primary advanced or recurrent endometrial cancer.